Literature DB >> 26523340

Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus.

Vivek Sabharwal1, Eugene Ramsay2, Raisa Martinez3, Rachel Shumate1, Fawad Khan1, Hina Dave1, Ifeanyi Iwuchukwu1, Harold McGrade1.   

Abstract

Retrospective analysis was conducted of patients with SRSE who were treated simultaneously with propofol and ketamine. Sixty-seven patients were identified from 2012 to 2015, and outcomes documented were resolution and mortality. The duration of combined ketamine and propofol use ranged from 1 to 28 days (mean - 3.6 days). Infusion rates ranged up to 145 and 175 mcg/kg/min. Vasopressors were used in 53 patients (79%), and were given within the first 5 days of the ICU admission in 48 (91%) patients. The overall SRSE resolution rate was 91%, and the overall mortality including patients with anoxic brain injury was 39%. Of the 13 patients with SRSE as a result of anoxic brain injury, SRSE was controlled in 5 (56%). The primary determinant of mortality was family withdrawing care related to the presence of severe medical/neurological diseases.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anesthetic agents; Ketamine; Mortality; Propofol; Seizure control; Super-refractory status epilepticus; Treatment

Mesh:

Substances:

Year:  2015        PMID: 26523340     DOI: 10.1016/j.yebeh.2015.07.040

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  15 in total

1.  Ketamine for Refractory Status Epilepticus: A Systematic Review.

Authors:  Anna Rosati; Salvatore De Masi; Renzo Guerrini
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

Review 2.  Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults.

Authors:  Martin Holtkamp
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

3.  Independent Functional Outcomes after Prolonged Coma following Cardiac Arrest: A Mechanistic Hypothesis.

Authors:  Peter B Forgacs; Orrin Devinsky; Nicholas D Schiff
Journal:  Ann Neurol       Date:  2020-02-11       Impact factor: 10.422

4.  Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee.

Authors:  David G Vossler; Jacquelyn L Bainbridge; Jane G Boggs; Edward J Novotny; Tobias Loddenkemper; Edward Faught; Marta Amengual-Gual; Sarah N Fischer; David S Gloss; Donald M Olson; Alan R Towne; Dean Naritoku; Timothy E Welty
Journal:  Epilepsy Curr       Date:  2020-08-21       Impact factor: 7.500

5.  Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits.

Authors:  Jerome Niquet; Roger Baldwin; Keith Norman; Lucie Suchomelova; Lucille Lumley; Claude G Wasterlain
Journal:  Epilepsia       Date:  2016-08-08       Impact factor: 5.864

6.  Ketamine to treat super-refractory status epilepticus.

Authors:  Ayham Alkhachroum; Caroline A Der-Nigoghossian; Elizabeth Mathews; Nina Massad; Riva Letchinger; Kevin Doyle; Wei-Ting Chiu; Julie Kromm; Clio Rubinos; Angela Velazquez; David Roh; Sachin Agarwal; Soojin Park; E Sander Connolly; Jan Claassen
Journal:  Neurology       Date:  2020-09-01       Impact factor: 9.910

Review 7.  Status epilepticus - time is brain and treatment considerations.

Authors:  Caroline Der-Nigoghossian; Clio Rubinos; Ayham Alkhachroum; Jan Claassen
Journal:  Curr Opin Crit Care       Date:  2019-12       Impact factor: 3.687

Review 8.  Pharmacotherapy for Pediatric Convulsive Status Epilepticus.

Authors:  Avantika Singh; Coral M Stredny; Tobias Loddenkemper
Journal:  CNS Drugs       Date:  2020-01       Impact factor: 5.749

Review 9.  Super-Refractory Status Epilepticus: Prognosis and Recent Advances in Management.

Authors:  Batool F Kirmani; Katherine Au; Lena Ayari; Marita John; Padmashri Shetty; Robert J Delorenzo
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

10.  (S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study.

Authors:  Julia Höfler; Alexandra Rohracher; Gudrun Kalss; Georg Zimmermann; Judith Dobesberger; Georg Pilz; Markus Leitinger; Giorgi Kuchukhidze; Kevin Butz; Alexandra Taylor; Helmut Novak; Eugen Trinka
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.